Quality of Life Research

, Volume 6, Issue 1, pp 0–0 | Cite as

A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation

  • A. George Awad
  • L. N. P. Voruganti
  • R. J. Heslegrave

Abstract

The utility of quality of life (QOL) as an evaluative tool in clinical psychiatric research and drug trials could be enhanced by developing appropriate conceptual models of QOL, specific for psychiatric disorders. In our proposed model, QOL of individuals maintained on antipsychotic drug therapy for schizophrenia, is viewed as the subject's perception of the outcome of an interaction between severity of psychotic symptoms, side-effects including subjective responses to antipsychotic drugs, and the level of psychosocial performance. In order to test the validity of the model in clinical setting, we selected a sample of 62 schizophrenic patients clinically stabilized on antipsychotic drug therapy, and measured their subjective QOL and other potentially relevant clinical and psychosocial factors. Standardized scales including the positive and negative syndromes scale (PANSS), abnormal involuntary movements scale (AIMS), Hillside Akathisia scale (HAI), and the social performance schedule (SPS) were used for this purpose. Results of a multiple regression analysis using subjective quality of life as the outcome variable, indicated that severity of schizophrenic symptoms (partial R2=0.32, p < 0.0001) and subjective distress caused by akathisia (partial R2=0.11, p < 0.01) and neuroleptic dysphoria (partial R2=0.06, p < 0.05), accounted for nearly half of the variance, while the contribution from the psychosocial indicators was negligible. These results broadly endorse key aspects of the proposed model, and suggest further studies in this direction. These results suggest that improvement in patients' subjective experiences during antipsychotic therapy can enhance patients' QOL. This conceptual model has been developed with particular focus on the impact of antipsychotic medications on the QOL of persons with schizophrenia. As such, it is more applicable to clinical trials of new antipsychotic medications but may not be broad enough to be applicable for other social or vocational interventions.

Conceptual models quality of life schizophrenia 

References

  1. 1.
    Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry 1990; 41: 892-897.Google Scholar
  2. 2.
    Awad AG, Voruganti LNP, Heslegrave RJ. Measurement of quality of life in schizophrenia. PharmacoEconomics (in press)Google Scholar
  3. 3.
    Lancet. Quality of life and clinical trials. Lancet 1995; 346: 1-2.Google Scholar
  4. 4.
    Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Comm Psychiatry 1992; 43: 262-265.Google Scholar
  5. 5.
    Awad AG. Methodological and design issues in clinical trials of new neuroleptics: an overview. Br J Psychiatry 1993; 163(Suppl. 22): 51-57.Google Scholar
  6. 6.
    Awad A. Quality of life issues in medicated schizophrenics: therapeutic and research implications. In: Contemporary Issues in the Treatment of Schizophrenia. Shariqui CL, Nasrallah H, eds. Washington DC: American Psychiatric Press, 1995.Google Scholar
  7. 7.
    Lehman A, Ward N, Linn L. Chronic mental patients: the quality of life issue. Am J Psychiatry 1982; 139: 1271-1276.Google Scholar
  8. 8.
    Lehman A. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychitatry 1983; 40: 369-373.Google Scholar
  9. 9.
    Lehman A. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval Prog Plan 1983; 6: 143-151.Google Scholar
  10. 10.
    Lehman A, Possidente S, Hawker F. The quality of life of chronic patients in a state hospital and in community residences. Hosp Comm Psychiatry 1986; 37: 901-907.Google Scholar
  11. 11.
    Sullivan G, Wells K, Leake B. Quality of life of seriously mentally ill persons in Mississippi. Hosp Comm Psychiatry 1991; 42: 752-754.Google Scholar
  12. 12.
    Levitt AJ, Hogan TP, Bucosky CM. Quality of life in chronically mentally ill patients in day treatment. Psychological Med 1990; 20: 703-710.Google Scholar
  13. 13.
    Corten P, Mercier C, Pelc I. "subjective quality of life’: clinical model for assessment of rehabilitation treatment in psychiatry. Soc Psychiatry Psychiatr Epidemiol 1994; 29: 178-183.Google Scholar
  14. 14.
    Gill T, Feinstein A. A critical appraisal of the quality of life measurements. JAMA 1994; 272: 619-626.Google Scholar
  15. 15.
    Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schiz Bull 1987; 13: 261.Google Scholar
  16. 16.
    Fleishhacker WW, Bergmann KJ, Perovich R, et al. The Hillside Akathisia Scale: A new rating instrument for neuroleptic induced akathisia. Psychopharm Bull 1989; 25: 222-226.Google Scholar
  17. 17.
    Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976. Washington DC: US Department of Health, Education and Welfare, 1976.Google Scholar
  18. 18.
    Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Med 1983; 13: 177-183.Google Scholar
  19. 19.
    Hogan T, Awad A. Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures. Psychological Med 1992; 22: 347-352.Google Scholar
  20. 20.
    Wykes T, Stuart E. The measurement of social behaviour in psychiatric patients: an assessment of the reliability and validity of the SBS schedule. Br J Psychiatry 1986; 148: 1-11.Google Scholar
  21. 21.
    Endicott J, Spitzer RL, Fleiss JL, et al. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-771.Google Scholar
  22. 22.
    Gurin G, Verhoff J, Feld S. Americans View Their Mental Health. New York, NY: Russel Sage Foundation, 1960.Google Scholar
  23. 23.
    Bachrach L. Deinstitutionalization: An Analytic Review and Sociological Perspective. Rockville, MD: National Institute of Mental Health, 1976.Google Scholar
  24. 24.
    Strauss JS. Subjective experiences of schizophrenia: towards a new dynamic psychiatry. Schiz Bull 1987 15: 178-179.Google Scholar
  25. 25.
    Singh MM, Kay SR. Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biolog Psychiatry 1979; 14: 277-294.Google Scholar
  26. 26.
    Van Putten T, May PRA, Marder SR. Subjective response to thiothixene and chlorpromazine. Psychopharma Bull 1980: 16-18.Google Scholar
  27. 27.
    Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharma Biolog Psychiatry 1985; 9: 585-588.Google Scholar
  28. 28.
    VanPutten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190.Google Scholar
  29. 29.
    Diamond R. Drugs and quality of life: The patient's point of view. J Clin Psychiatry 46(5): 29-35.Google Scholar
  30. 30.
    Awad AG. Subjective response to neuroleptics in schizophrenia. Schiz Bull 1993; 19: 609-617.Google Scholar
  31. 31.
    Awad AG, Hogan TP, Voruganti LNP, Heslegrave RJ. Patients' experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psyhcopharm 1995; 10(Suppl 3): 123-132Google Scholar
  32. 32.
    Brekke JS, Levin S, Wolkon GH et al. Psychosocial functioning and subjective experience in schizophrenia. Schiz Bull 1993; 19: 599-608.Google Scholar
  33. 33.
    Romney DM. Psychosocial functioning and subjective experience in schizophrenia: A reanalysis. Schiz Bull 1995; 21: 405-410.Google Scholar

Copyright information

© Chapman and Hall 1997

Authors and Affiliations

  • A. George Awad
    • 1
  • L. N. P. Voruganti
    • 2
  • R. J. Heslegrave
    • 1
  1. 1.Department of PsychiatryUniversity of TorontoTorontoCanada
  2. 2.Department of PsychiatryUniversity of Western OntarioLondonCanada

Personalised recommendations